The FDA delayed by an additional three months its approval decision on Johnson & Johnson's psoriasis treatment Stelara but did not ask for more clinical studies. "We remain focused on collaboration with the FDA and providing the necessary information to support the review and approval of Stelara for the treatment of adults with moderate to severe plaque psoriasis," J&J's chief biotechnology officer said.

Full Story:

Related Summaries